LabGenius Wins Government Innovation Grant to Scale ML-Based Drug Discovery Platform, EVA™

LONDON–(BUSINESS WIRE)–LabGenius, a pioneer in the use of machine learning (ML) for antibody engineering, today announced that it has been awarded a highly competitive SMART grant from Innovate UK. Grants from the £25m fund enable companies like LabGenius to realize the potential of new ideas by investing in groundbreaking, commercially viable research and development projects.

To date, LabGenius’ EVA The platform has been used to co-optimize mono- and multi-specific single domain antibodies for biochemical and biofunctional properties, including stability, potency and selective killing of tumor cells. This grant will be used to further develop EVAthe capacities by accelerating the platform’s ability to optimize antibody-based immune cell engagement molecules.

Many existing therapeutic antibodies have poor selective cell killing profiles, which can lead to on-target, off-tumor effects and treatment discontinuation. Using EVAs predictive power, LabGenius identifies non-intuitive protein designs, which perform well on several therapeutically valuable properties, including selective killing.

Commenting on the LabGenius funding allocation, UKRI Board Member Lord David Willetts said: “Machine learning holds real promise to transform the way we approach cancer detection and treatment. It is incredibly exciting to see LabGenius focus its efforts in this area of ​​therapeutic innovation by continuing to advance its ability to optimization of pathways for immune cell engagement.

“We are extremely proud to have received a SMART grant from Innovate UK” says LabGenius CEO and Founder, Dr. James Field. “This funding will help us realize the potential of computational technologies in R&D, as we believe they hold the key to accelerating the discovery and development of advanced therapies.”

Speaking about the company’s recent success, LabGenius Chief Scientific Officer Dr. Gino Van Heeke said: “Lead optimization is a critical part of the antibody discovery process, and this funding will allow us to further demonstrate the potential of our platform to use machine learning to accelerate the development of molecules with best-in-class properties. .”

– end –

About LabGenius

London-based LabGenius is a leading protein engineering company focused on machine learning. The company’s core technology platform, EVA™, enables the rapid discovery of new therapeutic antibodies. LabGenius’ highly multidisciplinary team brings together the best minds in the fields of computer science, robotic automation and synthetic biology.

For more information, visit www.labgeni.us or log on to TwitterLinkedIn and Medium.

About Armand Downs

Check Also

Week in Review: Insilico Signs Six AI-Drug Discovery Deal with Sanofi Worth Up to $1.2 Billion

jittawit.21 Offers and financing Insilico Medicine, a Hong Kong and New York-based AI drug discovery …